Dundee Research Interest Group

The best way to be considered for current or future trials is to join the 'Permission to Contact' scheme for the Neuroprogressive & Dementia Network.  This will allow the research team to access your medical records and check whether you are eligible for studies.  To find out more details please visit https://www.nhsresearchscotland.org.uk/research-areas/dementia-and-neurodegenerative-disease. 

To sign up for the 'Permission to Contact' scheme, please complete the online form https://www.nhsresearchscotland.org.uk/research-areas/dementia-and-neurodegenerative-disease/patient-signup-form. Alternatively you can email tay.ndntayside@nhs.scot or call 01382 423086 to have a paper form sent out.

Current available trials:

• RAPSODI GD 

Remote assessment of Parkinsonism supporting ongoing development of interventions in Gaucher disease

Open to new recruits: Yes

Study Drug: No

Inclusion criteria: Anyone with a diagnosis of Parkinson’s Disease

Participating Scottish sites: Dundee

Website: https://www.parkinsons.org.uk/research/pd-frontline-identifying-genes-people-parkinsons

• ABBVIE M15-741 & M15-737 

Safety and Tolerability of 24-Hour Daily Exposure to ABBV-951 by Continuous Subcutaneous Infusion

Open to new recruits: No

Study Drug: Yes: 24hour sub-cutaneous levodopa/carbidopa infusion pump 

Inclusion criteria: >30yo, idiopathic PD that is levodopa-responsive

Participating Scottish sites: Dundee

Website: https://clinicaltrials.gov/ct2/show/NCT04379050

• LIPAD

LRRK2/Luebeck International Parkinson's Disease Study Protocol: Deep Phenotyping of an International Genetic Cohort

Open to new recruits: Yes

Study Drug: No

Inclusion criteria: Involved in the ROPAD study. Parkinson’s diagnosis. Healthy volunteer.

Participating Scottish sites: Dundee

• PADOVA 

A Phase IIB, randomized, double-blind, placebo-controlled, multi-centre study to evaluate the efficacy and safety of intravenous Prasinezumab. 

Open to new recruits: No

Study Drug: Prasinezumab/placebo

Inclusion criteria: >50-85yo, PD diagnosis 6M-3yr at screening, 3m stable treatment

Participating Scottish sites? Dundee 

Website: https://forpatients.roche.com/en/trials/neurodegenerative-disorder/pd/a-study-to-evaluate-the-efficacy-and-safety-of-intraven-35605.html

• LUMA 

The Luminare Study is evaluating the safety and efficacy of a study drug, as compared to a placebo, to see if it may delay the progression of Parkinson’s disease in people who are in the early stage of their condition. 

Open to new recruits: Yes

Study Drug: BIIB122/placebo

Inclusion criteria: LUMA. 30-80 years old. Diagnosed with Parkinson’s disease within the last 2 years and were at least 30 years old when you were diagnosed.

Participating Scottish sites: Dundee

Website:  https://www.parkinsonsresearchstudies.com/?utm_source=parkinsonsfoundation&utm_medium=vanity&utm_campaign=luminare&utm_term=url&utm_content=luminarepdstudiesdotcom

• BIAL ACTIVATE

Safety and Tolerability of BIA 28-6156 in people with Parkinson's Disease with a pathogenic variant in the Glucocerebrosidase (GBA1) Gene

Open to new recruits: Yes

Study Drug:  BIA 28-6156

Inclusion Criteria:  Between 30-80 yrs old, diagnosis of PD in last 7 years and a genetic screening to determine if the participant will qualify for the study

Participating Scottish Sites:  Dundee

Website:  https://bial.com/com/our-research/pipeline/bia-28-6156/

• CAN PDP

CANnabidiol for Parkinson’s Disease Psychosis

Open to New recruits:  Yes

Study Drug:  CBD/placebo

Inclusion Criteria:  over 40 years old, experienced symptoms of psychosis for at least 1 month, been taking PD medication for at least 1 month, 

Participating Scottish Sites:  Aberdeen, Dundee, Edinburgh

Website:  https://www.parkinsons.org.uk/research/can-pdp-cannabidiol-cbd-people-parkinsons-who-experience-hallucinations-or-delusions

- For further information of other research studies:  https://bepartofresearch.nihr.ac.uk/

Dr Esther Sammler of the Dundee MRC-PPU Lab has kindly provided an updated list of on-going research in various neurological fields, pages 2 and 3 list all of the current Parkinson's Disease trials.  Please have a look through the document here:

We are looking for PwPs who also suffer regularly from visual hallucinations.  Please see the attached document for details and do pass on to any PWPs who you may know who suffer from hallucinations and would be interested in taking part, thank you.

Anyone who would like more information should contact Kate Ferguson at

Academia led project: LIPAD - LRRK2 International Parkinson’s Disease Study an international, multicenter, epidemiological observational study for people with PD. This is a very exciting study led by Professor Christine Klein in Germany with Dr Esther Sammler as the lead for the UK. They now have ethics approval and are hoping to start recruiting very soon.

Sponsor: University of Luebeck, Investigator: Dr. Esther Sammler

Recent research has shown that genetics play an important role in Parkinson’s disease. Promising drugs designed to slow down the progression of Parkinson’s disease are being developed and many of these are designed to counteract specific genetic abnormalities. Genetic testing for these abnormalities is increasingly being carried out. We hope in the near future this will allow participation in drug trials. PD Frontline is an online study which allows you undertake these genetic tests. We are actively recruiting for this study.

Sponsor: University College London, Local Investigator: Dr. Esther Sammler